omeprazole has been researched along with desloratadine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Naidong, W; Song, Q; Zhou, S; Zhou, W | 1 |
| Bourke, J; Roper, S | 1 |
| Li, X; Wang, W; Wang, Y; Wu, W; Xu, Q; Zhang, J; Zhang, T; Zhang, Y | 1 |
1 review(s) available for omeprazole and desloratadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for omeprazole and desloratadine
| Article | Year |
|---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Direct injection of 96-well organic extracts onto a hydrophilic interaction chromatography/tandem mass spectrometry system using a silica stationary phase and an aqueous/organic mobile phase.
Topics: Chromatography, Liquid; Humans; Loratadine; Omeprazole; Pharmaceutical Preparations; Piperidines; Protease Inhibitors; Pyridines; Reserpine; Spectrometry, Mass, Electrospray Ionization | 2004 |
In with the new: the determinants of prescribing innovation by general practitioners in Ireland.
Topics: Age Factors; Androstenes; Citalopram; Drug Prescriptions; Drug Utilization; Ethinyl Estradiol; General Practitioners; Humans; Information Dissemination; Insurance Claim Review; Ireland; Lactones; Loratadine; Nicotine; Omeprazole; Practice Patterns, Physicians'; Residence Characteristics; Sulfones; Therapies, Investigational; Time Factors | 2012 |
Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction.
Topics: Administration, Oral; Animals; Chromatography, Liquid; Dogs; Drug Interactions; Loratadine; Male; Omeprazole; Tandem Mass Spectrometry | 2021 |